
MTM - The Role of Repurposed Drugs in Treating Cancer
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
このコンテンツについて
Send us a text
Dr. Robert Jackson tackles the controversial yet increasingly compelling topic of repurposed drugs in cancer treatment, sharing remarkable patient stories that challenge conventional medical thinking.
Meet the bladder cancer patient given no hope by her oncologist who achieved complete remission through mistletoe injections. Learn about Joe Tippin, the sole survivor in a lung cancer study who credits mebendazole—an inexpensive anti-parasitic medication—for his recovery. Perhaps most striking is the case of a terminal gallbladder cancer patient told to "get his affairs in order" who showed no evidence of disease after taking ivermectin, mebendazole, and vitamin D3.
While acknowledging the limitations of anecdotal evidence, Dr. Jackson examines emerging clinical data supporting these approaches. The CUSP9 study using nine repurposed drugs showed 30% of glioblastoma patients disease-free after four years—dramatically better than the 5-10% typical with standard care. The METRICS study achieved 64% two-year survival in advanced glioblastoma using four common medications repurposed for cancer treatment.
Dr. Jackson doesn't just talk the talk. When facing a suspected kidney cancer diagnosis himself, he immediately started taking mebendazole while awaiting surgery. "What have you got to lose?" he asks, noting these medications provide an affordable margin of safety alongside conventional treatments.
Are pharmaceutical companies avoiding research into these approaches because there's no profit in off-patent medications? Why aren't more oncologists exploring these options? Listen now to this thought-provoking episode that might just change how you think about cancer treatment options.
Support the show
https://www.jacksonfamilyministry.com
https://bobslone.com/home/podcast-production/